June 9, 2008 – Avid Radiopharmaceuticals, Inc. announced the start of a Phase II clinical trial studying 18F-AV-45, an investigational molecular imagin compound under development for imaging Alzheimer’s disease. 18F-AV-45 is used with positron emission tomography (PET) to allow visualization of the amyloid plaque deposits in the brain that are characteristic of Alzheimer’s disease. Amyloid plaque is thought to slowly accumulate in patients over years, eventually causing death of brain cells and dementia. This is the first large scale multi-center trial of an 18F-labeled PET molecular imaging agent for visualizing amyloid plaques... [PDF] Avid Radiopharmaceuticals' Press Release -
Monday, June 16, 2008
Avid Radiopharmaceuticals : First Phase II Trial of Novel Compound for Imaging Alzheimer’s Disease
June 9, 2008 – Avid Radiopharmaceuticals, Inc. announced the start of a Phase II clinical trial studying 18F-AV-45, an investigational molecular imagin compound under development for imaging Alzheimer’s disease. 18F-AV-45 is used with positron emission tomography (PET) to allow visualization of the amyloid plaque deposits in the brain that are characteristic of Alzheimer’s disease. Amyloid plaque is thought to slowly accumulate in patients over years, eventually causing death of brain cells and dementia. This is the first large scale multi-center trial of an 18F-labeled PET molecular imaging agent for visualizing amyloid plaques... [PDF] Avid Radiopharmaceuticals' Press Release -
